Women’s HealthcareWomen Are Turning to Testosterone, but What Does the Science Actually Say?

🎓 Expert Commentary / Peer Perspective

Women seeking relief from menopause symptoms may encounter claims that testosterone improves libido, mood, cognition, and energy. This explainer distinguishes evidence supporting treatment of postmenopausal hypoactive sexual desire disorder (HSDD) from less certain benefits beyond sexual function. It cites randomized-trial evidence and international guidance alongside an uncontrolled clinic study. Product-access barriers and dosing concerns add counseling value, but neither rising demand nor patient-reported improvement establishes broader efficacy. Long-term cardiovascular and breast safety remain insufficiently characterized.

Patient Counseling Points

• HSDD involves persistent low desire that causes distress, not simply a lower testosterone result or an age-related change in sexual interest.
• The cited trial synthesis supports sexual-function benefits in selected postmenopausal women; it does not establish testosterone as general menopause therapy.
• Mood and cognitive improvements reported by 510 clinic patients were observational; concurrent treatments and other influences prevent causal attribution.
• Testosterone does not fall sharply at natural menopause like estrogen. Measurement challenges also complicate claims of a straightforward hormone “deficiency.”
• Excess exposure can cause acne and increased facial or body hair. Improvised dosing of male formulations raises precision concerns.
• Long-term safety remains uncertain, particularly for cardiovascular events and breast cancer; short trials and selected populations limit reassurance.

Patient Care Applications

• Clarify the difference between evidence-supported HSDD treatment and unproven claims for energy, cognition, or general well-being.
• Discuss distress, relationships, mental health, medications, and other contributors to low desire rather than attributing symptoms to testosterone alone.
• Warn against unsupervised acquisition or improvised dosing; discuss formulation, monitoring, and safety uncertainties when treatment is being considered.